AB-DR7™ updated clinical results

20 May 2021 – 1 min read

L. plantarum DR7 is a probiotic strain with multiple proven therapeutic benefits, and great potential for immune health. Its most remarkable clinical trial tests the probiotic as a treatment for Upper Respiratory Tract Infections (URTIs). The study demonstrated the immunomodulatory effect of L. plantarum DR7, that was able to alleviate the symptoms of URTI by reducing the duration of nasal symptoms and frequency of infections after 12 weeks of administration.

Although results of the clinical trial were promising and published on a relevant journal, AB-BIOTICS has kept increasing the research behind the product, with a recent re-analysis of clinical data. On this post-hoc analysis, the probiotic solution improved URTI severity, reducing patient-days with URTI by 20%, and patient-days with fever by 27%. Therefore, the strain showed the ability to increase recovery process of respiratory tract infections, If treatment was taken for at least 3 months as a preventive, long term measure.

The strain is found in AB-DR7, a product already widely distributed worldwide, that in some countries also contains Vitamin C on its formulation.

AB-DR7™ presents as a solution to prevent the appearance of URTI symptoms in risky periods or reduce URTI severity

Lipigo origin

As usually happens with probiotics, AB-DR7 has to be taken for some time to experience all its therapeutic benefits. Therefore, the product presents as a great solution to take when foreseeing risky infection periods (wintertime, for example) or ideal for risky populations, like elderly or children starting day-care.

The mechanism of AB-DR7 effects on respiratory health has also been studied in depth. With multiple effects on the immune system, the probiotic has been shown to:

  • Reduce inflammation and oxidative stress, through the regulation of several inflammatory markers
  • Downregulate the tryptophan-kynurenine pathway, with effects on the synthesis of several neurotransmitters
  • Inhibit the growth of pathogens directly linked with the pathophysiology of URTIs, including Staphylococcus aureus and Streptococcus pneumoniae

Check AB-DR7™ post-hoc analysis here

Authors: Claudia Prat (Human Biologist)